PDS Biotechnology Corp

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

PDSB$1.03-4.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity

Common Stock · Additional
	Shares Issued	Amount	Paid-in Capital	Accumulated Deficit	Total Equity
January 1, 2025	37,987,380	$12,536	$201,103,311	$(182,110,999)	$19,004,848
Stock-based compensation expense	-	-	1,253,882	-	1,253,882
Issuance of common stock for consulting agreement	150,000	50	203,451	-	203,501
Issuance of common stock from at-the-market program, net	205,350	68	306,047	-	306,115
Issuances of common stock, net of issuance costs	6,396,787	2,111	6,919,908	-	6,922,019
Issuance of pre-funded warrants	-	-	1,009,969	-	1,009,969
Issuance of warrants	-	-	2,150,771	-	2,150,771
Exercise of pre-funded warrants	706,334	233	(162)	-	71
Net loss	-	-	-	(8,488,967)	(8,488,967)
Balance - March 31, 2025	45,445,851	$14,998	$212,947,177	$(190,599,966)	$22,362,209
Stock-based compensation expense	-	-	448,029	-	448,029
Issuance of common stock from at-the-market program, net	960,511	317	1,460,325	-	1,460,642
Issuances of common stock, net of issuance costs	-	-	50,000	-	50,000
Issuance of warrants	-	-	1,073,089	-	1,073,089
Exercise of pre-funded warrants	227,000	75	(52)	-	23
Net loss	-	-	-	(9,434,208)	(9,434,208)
Balance - June 30, 2025	46,633,362	$15,390	$215,978,568	$(200,034,174)	$15,959,784

Common Stock · Additional
	Shares Issued	Amount	Paid-in Capital	Accumulated Deficit	Total Equity
January 1, 2026	54,878,233	$18,111	$225,840,226	$(216,606,504)	$9,251,833
Stock-based compensation expense	-	-	1,156,495	-	1,156,495
Issuance of common stock from at-the-market program, net	937,420	309	833,062	-	833,371
Net loss	-	-	-	(7,349,056)	(7,349,056)
Balance - March 31, 2026	55,815,653	$18,420	$227,829,783	$(223,955,560)	$3,892,643
Stock-based compensation expense	-	-	1,126,054	-	1,126,054
Issuance of common stock from at-the-market program, net	106,153	35	97,196	-	97,231
Issuance of warrants	-	-	1,054,908	-	1,054,908
Net loss	-	-	-	(9,750,575)	(9,750,575)
Balance - June 30, 2026	55,921,806	$18,455	$230,107,941	$(233,706,135)	$(3,579,739)

Index

Condensed Consolidated

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.